Professional Role and Responsibilities
Adam D'Augelli is a Partner at True Ventures, a Silicon Valley-based early-stage venture capital firm founded in 2005, with offices in San Francisco and Palo Alto. His partnership role involves identifying and supporting promising entrepreneurs and startups, primarily focusing on early-stage investments. Adam specializes in medical devices, analytics, and artificial intelligence sectors, reflecting a targeted investment profile within cutting-edge technology and life sciences.
Investment Track Record
Adam has led and contributed to numerous successful investments in emerging technology companies, with notable portfolio companies including:
- Pendulum Therapeutics
- Deep Genomics
- InterVenn Biosciences
- RadiantGraph
- Flipside Crypto
- Runscope
- Ginger.io
- Moleculo (which was acquired by Illumina in 2013)
His investment activity spans multiple funding rounds, including leading or co-investing in seed and series B stages. For example, his recent contributions include:
- Deduce: Series B funding of $9M in September 2023, seed funding of $7M in November 2020, totaling over $26M across rounds.
- ClayStack: Seed funding round of $5.2M in July 2021 alongside 36 other investors.
These investments reflect significant capital deployment across companies driving innovation in life sciences, AI, and analytics.
Industry and Board Involvement
Adam joined the National Venture Capital Association's (NVCA) Board of Directors in 2025, with a four-year term through 2029, supporting the NVCA’s advocacy and advancement efforts in the venture capital industry. His position on the NVCA board highlights his leadership role and influence within the broader venture capital community, particularly in advocating for emerging technologies and regulatory frameworks.
Educational Background and Honors
Adam graduated magna cum laude from the University of Florida, earning both a Bachelor of Science and a Master’s degree in Finance from the Warrington College of Business. His academic distinctions include:
- Warrington Finance Scholar
- Outstanding Anderson Scholar
- Four Year Outstanding Academic Performance Award
- Participation in the Florida Leadership Academy
These honors underscore a strong academic foundation combining scientific rigor and financial expertise, supporting his capacity to evaluate and grow technology ventures.
Previous Experience
Before fully assuming his role at True Ventures, Adam had operational experience, including running Perfect Wave, which indicates direct entrepreneurial and operational insight. He also worked closely with True Ventures’ portfolio company B-Stock, an online marketplace specializing in liquidating excess inventory, providing him with hands-on experience in scaling marketplaces and operational business dynamics.
Professional Network and Influence
Adam maintains a robust professional network with over 7,000 followers and 500+ connections on LinkedIn, signaling broad industry recognition and reach. He actively engages on social platforms to promote and discuss innovations, particularly emphasizing translating scientific research into impactful medicines and technologies.
Summary of Key Professional Attributes
- Role: Partner at True Ventures, focused on early-stage venture capital
- Sectors of Expertise: Life Sciences, Medical Devices, AI, Analytics
- Significant Investments: Pendulum Therapeutics, Deep Genomics, InterVenn Biosciences, Runscope, Ginger.io, Moleculo
- Board Membership: NVCA Board of Directors (term 2025-2029)
- Academic Credentials: Magna cum laude graduate, Bachelor of Science and Master’s in Finance, University of Florida
- Industry Engagement: Active supporter and thought leader within the venture capital ecosystem
- Previous Operational Role: Founder/operator at Perfect Wave; prior work with B-Stock
Adam D'Augelli combines a strong technical and financial education with extensive venture capital experience and industry leadership, positioning him as a significant influencer in early-stage technology investments within True Ventures and the wider venture capital community.
